journal

Journal of Clinical Oncology

journal
https://read.qxmd.com/read/32639845/influence-of-surgical-excision-on-the-survival-of-patients-with-stage-4-high-risk-neuroblastoma-a-report-from-the-hr-nbl1-siopen-study
#1
Keith Holmes, Ulrike Pötschger, Andrew D J Pearson, Sabine Sarnacki, Giovanni Cecchetto, Javier Gomez-Chacon, Roly Squire, Enrique Freud, Adam Bysiek, Lucas E Matthyssens, Martin Metzelder, Tom Monclair, Jakob Stenman, Michal Rygl, Lars Rasmussen, Jean-Marc Joseph, Sabine Irtan, Stefano Avanzini, Jan Godzinski, Kristin Björnland, Martin Elliott, Roberto Luksch, Victoria Castel, Shifra Ash, Walentyna Balwierz, Geneviève Laureys, Ellen Ruud, Vassilios Papadakis, Josef Malis, Cormac Owens, Henrik Schroeder, Maja Beck-Popovic, Toby Trahair, Ana Forjaz de Lacerda, Peter F Ambros, Mark N Gaze, Kieran McHugh, Dominique Valteau-Couanet, Ruth Lydia Ladenstein
PURPOSE: To evaluate the impact of surgeon-assessed extent of primary tumor resection on local progression and survival in patients in the International Society of Pediatric Oncology Europe Neuroblastoma Group High-Risk Neuroblastoma 1 trial. PATIENTS AND METHODS: Patients recruited between 2002 and 2015 with stage 4 disease > 1 year or stage 4/4S with MYCN amplification < 1 year who had completed induction without progression, achieved response criteria for high-dose therapy (HDT), and had no resection before induction were included...
July 8, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/32634335/reply-to-l-h-einhorn-et-al
#2
Deaglan McHugh, George J Bosl, Samuel A Funt, Darren R Feldman
No abstract text is available yet for this article.
July 7, 2020: Journal of Clinical Oncology
https://read.qxmd.com/read/32634334/adjuvant-etoposide-plus-cisplatin-for-patients-with-pathologic-stage-ii-nonseminomatous-germ-cell-tumors-is-this-the-preferred-option
#3
LETTER
Lawrence H Einhorn, Nabil Adra, Nasser Hanna, Craig Nichols
No abstract text is available yet for this article.
July 7, 2020: Journal of Clinical Oncology
https://read.qxmd.com/read/32614703/reply-to-r-t-chlebowski-et-al
#4
Jennifer A Ligibel
No abstract text is available yet for this article.
July 2, 2020: Journal of Clinical Oncology
https://read.qxmd.com/read/32614702/differential-benefit-of-adjuvant-docetaxel-based-chemotherapy-in-patients-with-early-breast-cancer-according-to-baseline-body-mass-index
#5
Christine Desmedt, Marco Fornili, Florian Clatot, Romano Demicheli, Davide De Bortoli, Angelo Di Leo, Giuseppe Viale, Evandro de Azambuja, John Crown, Prudence A Francis, Christos Sotiriou, Martine Piccart, Elia Biganzoli
PURPOSE: Lipophilic drugs, such as taxanes, have a high affinity for adipose tissue and a resulting higher volume of distribution. Here, we reanalyzed clinical trial data to investigate whether the efficacy of docetaxel-based chemotherapy differs from non-docetaxel-based chemotherapy in patients with breast cancer according to their baseline body mass index (BMI). PATIENTS AND METHODS: We retrospectively analyzed data from all of the patients in the adjuvant BIG 2-98 trial (ClinicalTrials...
July 2, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/32614701/dietary-moderation-and-deaths-from-breast-cancer
#6
LETTER
Rowan T Chlebowski, Aaron K Aragaki, Ross L Prentice
No abstract text is available yet for this article.
July 2, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/32614700/now-more-than-ever-is-the-time-for-early-and-frequent-advance-care-planning
#7
Abby R Rosenberg, Beth Popp, Don S Dizon, Areej El-Jawahri, Rebecca Spence
No abstract text is available yet for this article.
July 2, 2020: Journal of Clinical Oncology
https://read.qxmd.com/read/32614699/teriparatide-promotes-bone-healing-in-medication-related-osteonecrosis-of-the-jaw-a-placebo-controlled-randomized-trial
#8
Ie-Wen Sim, Gelsomina L Borromeo, Claudine Tsao, Rita Hardiman, Michael S Hofman, Christian Papatziamos Hjelle, Musib Siddique, Gary J R Cook, John F Seymour, Peter R Ebeling
PURPOSE: Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent but morbid and potentially serious condition associated with antiresorptive and antiangiogenic therapies. Although MRONJ can be prevented by optimizing oral health, management of established cases is supportive and remains challenging. Teriparatide, an osteoanabolic agent that improves bone healing in preclinical studies and in chronic periodontitis, represents a potential treatment option. PATIENTS AND METHODS: In a double-blind, randomized, controlled trial, 34 participants with established MRONJ, with a total of 47 distinct MRONJ lesions, were allocated to either 8 weeks of subcutaneous teriparatide (20 µg/day) or placebo injections, in addition to calcium and vitamin D supplementation and standard clinical care...
July 2, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/32614698/pyrotinib-in-her2-mutant-advanced-lung-adenocarcinoma-after-platinum-based-chemotherapy-a-multicenter-open-label-single-arm-phase-ii-study
#9
Caicun Zhou, Xingya Li, Qiming Wang, Guanghui Gao, Yiping Zhang, Jianhua Chen, Yongqian Shu, Yanping Hu, Yun Fan, Jian Fang, Gongyan Chen, Jun Zhao, Jianxing He, Fengying Wu, Jianjun Zou, Xiaoyu Zhu, Xiang Lin
PURPOSE: Targeted therapies against non-small-cell lung cancer (NSCLC) harboring HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of pyrotinib in patients with HER2 -mutant advanced NSCLC in a prospective, multicenter, open-label, single-arm, phase II study. PATIENTS AND METHODS: Patients with stage IIIB or IV HER2 -mutant lung adenocarcinoma who were previously treated with platinum-based chemotherapy were enrolled to receive pyrotinib at a dose of 400 mg/d for 21-day cycles...
July 2, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/32603244/bone-mineral-density-and-frax-score-may-not-predict-fracture-risk-in-patients-with-cancer-undergoing-hormone-deprivation-therapies
#10
Alberto Dalla Volta, Gherardo Mazziotti, Filippo Maffezzoni, Salvatore Grisanti, Carlotta Palumbo, Rebecca Pedersini, Roberto Maroldi, Alfredo Berruti
No abstract text is available yet for this article.
June 30, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/32584633/jaipur-journey
#11
Keerthi Gondy
No abstract text is available yet for this article.
June 25, 2020: Journal of Clinical Oncology
https://read.qxmd.com/read/32584632/journal-honors-rahul-s-vedula-md-as-recipient-of-the-2020-journal-of-clinical-oncology-young-investigator-award
#12
Christine Melchione
No abstract text is available yet for this article.
June 25, 2020: Journal of Clinical Oncology
https://read.qxmd.com/read/32584631/performance-status-in-cancer-not-broken-but-time-for-an-upgrade
#13
Jessica M Scott, Guro Stene, Elisabeth Edvardsen, Lee W Jones
No abstract text is available yet for this article.
June 25, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/32584630/efficacy-and-safety-of-vandetanib-in-progressive-and-symptomatic-medullary-thyroid-cancer-post-hoc-analysis-from-the-zeta-trial
#14
Michael C Kreissl, Lars Bastholt, Rossella Elisei, Robert Haddad, Ole Hauch, Barbara Jarząb, Bruce Robinson, Raffaella Colzani, Meredith Foster, Richard Weiss, Martin Schlumberger
PURPOSE: We conducted a post hoc analysis of the vandetanib phase III trial involving patients with advanced medullary thyroid cancer (MTC) to assess the efficacy and safety of vandetanib in patients with progressive and symptomatic MTC. The primary objective of the analysis was to determine progression-free survival (PFS) of these patients. PATIENTS AND METHODS: Eligible patients from the ZETA trial were divided into 4 disease severity subgroups: progression and symptoms, symptoms only, progression only, and no progression and no symptoms assessed at baseline...
June 25, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/32574119/reply-to-g-w-peters-et-al-and-s-shi-et-al
#15
Eileen M O'Reilly, Cristina Ferrone
No abstract text is available yet for this article.
June 23, 2020: Journal of Clinical Oncology
https://read.qxmd.com/read/32574118/neoadjuvant-treatment-for-pancreatic-cancer-still-a-controversial-issue
#16
LETTER
Si Shi, Jie Hua, Xianjun Yu
No abstract text is available yet for this article.
June 23, 2020: Journal of Clinical Oncology
https://read.qxmd.com/read/32574117/randomized-trial-comparing-double-versus-triple-bortezomib-based-regimen-in-patients-with-multiple-myeloma-and-acute-kidney-injury-due-to-cast-nephropathy
#17
Frank Bridoux, Bertrand Arnulf, Lionel Karlin, Nicolas Blin, Nolwenn Rabot, Margaret Macro, Vincent Audard, Karim Belhadj, Brigitte Pegourie, Pierre Gobert, Emilie Cornec Le Gall, Bertrand Joly, Alexandre Karras, Arnaud Jaccard, Karine Augeul-Meunier, Salomon Manier, Bruno Royer, Denis Caillot, Mourad Tiab, Sébastien Delbes, Felipe Suarez, Cécile Vigneau, Sophie Caillard, Nina Arakelyan-Laboure, Damien Roos-Weil, Sylvie Chevret, Jean Paul Fermand
PURPOSE: We report a multicenter controlled trial comparing renal recovery and tolerance profile of doublet versus triplet bortezomib-based regimens in patients with initial myeloma cast nephropathy (CN) and acute kidney injury (AKI) without need for dialysis. METHODS: After symptomatic measures and high-dose dexamethasone, patients were randomly assigned to receive bortezomib plus dexamethasone (BD), or BD plus cyclophosphamide (C-BD). In patients with < 50% reduction of serum free light chains (sFLCs) after 3 cycles, chemotherapy was reinforced with either cyclophosphamide (BD group) or thalidomide (C-BD group)...
June 23, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/32574116/reply-to-s-shi-et-al-and-g-w-peters-et-al
#18
Geertjan van Tienhoven, Eva Versteijne, Aeilko H Zwinderman, Cornelis J Punt, Casper H van Eijck
No abstract text is available yet for this article.
June 23, 2020: Journal of Clinical Oncology
https://read.qxmd.com/read/32574115/time-to-reconsider-staging-laparoscopy-in-pancreatic-cancer
#19
LETTER
Gabrielle W Peters, Christopher L Hallemeier, Krishan R Jethwa
No abstract text is available yet for this article.
June 23, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/32574114/health-related-quality-of-life-in-patients-with-hodgkin-lymphoma-a-longitudinal-analysis-of-the-german-hodgkin-study-group
#20
Stefanie Kreissl, Horst Müller, Helen Goergen, Julia Meissner, Max Topp, Martin Sökler, Jana Markova, Jürg Bernhard, Richard Greil, Bastian von Tresckow, Karolin Behringer, Jens-Ulrich Rüffer, Hans-Henning Flechtner, Michaela Möstl, Michael Fuchs, Andreas Engert, Volker Diehl, Peter Borchmann
PURPOSE: Many important details of health-related quality of life (HRQoL) after diagnosis and treatment of Hodgkin lymphoma (HL) are still unknown because large longitudinal studies of HRQoL are rare. Therefore, we analyzed a systematically assessed, comprehensive range of HRQoL domains in patients with HL of all stages from diagnosis up to 5 years of survivorship. PATIENTS AND METHODS: We included patients with HL age 18-60 years at diagnosis from the German Hodgkin Study Group trials HD13, HD14, and HD15...
June 23, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
journal
journal
20146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"